The reduced risk and severity of heart failure associated with use of an SGLT2 inhibitor, particularly HFrEF, provides a potentially important contribution to the reduced occurrence and better prognosis of AKI with this class of glucose-lowering agents [63••, 64]. The gene discussed is SLC5A2; the disease is heart failure.